The evidence on hormonal health, bone density, cardiovascular risk, and cognitive protection — graded by human trial data.
Reviewed by The Founder · Diplomate ABAAHP · 47 Years in Nutrition and Clinical Health
·
Context
Why Women's Longevity Is Different
Biology, not bias. The evidence gaps and biological realities that make women's longevity a distinct field.
01
Hormonal transitions accelerate biological aging
Estrogen loss affects bone, cardiovascular, brain, and metabolic health simultaneously. These are measurable, documentable changes — not subjective symptoms. The biological clock shifts faster during perimenopause than at any other adult life stage.
02
The longevity research base skews male
Many landmark supplement trials enrolled predominantly or exclusively men. EBL flags this explicitly on every page where the evidence base has a male bias. Where female-specific sub-analyses exist, those data are prioritized.
03
The 10-15 year window is the critical period
The window around menopause — perimenopause through early post-menopause — is when interventions have the greatest measurable impact on long-term outcomes. Acting before the window closes matters more than the specific intervention chosen.
Graded by Human Trial Data
Evidence-Ranked Interventions
Six core interventions with the strongest evidence base for women's longevity outcomes. Grades reflect published human RCT data.
Magnesium Glycinate
GRADE A
Bone · Sleep · Cardiovascular
Magnesium is the most widely deficient mineral in women over 40. Glycinate form maximizes absorption and avoids the laxative effect of oxide or citrate. Directly involved in bone matrix formation, sleep regulation, and vascular tone.
Key stat: 34% cardiovascular mortality reduction in the highest Mg quartile — PREDIMED sub-study ↗
D3 raises serum 25-OH vitamin D; K2 (MK-7) directs calcium into bone rather than arterial walls. Combined form addresses the two most consequential post-menopausal risks: bone loss and cardiovascular calcification.
Pharmaceutical-grade EPA+DHA at 4g/day produces meaningful reductions in cardiovascular events in high-risk populations. Post-menopausal women face an accelerating cardiovascular risk profile that makes this intervention particularly relevant.
CoQ10 is required for mitochondrial ATP production and is the rate-limiting nutrient for cellular energy. Ubiquinol is the reduced, more bioavailable form. Particularly important for statin users and anyone with fatigue as a primary complaint.
Creatine is the most studied ergogenic compound in human history with an exceptional safety record. Post-menopausal data consistently show preservation of lean mass, cognitive processing speed, and bone mineral density.
Particularly important post-menopause — sarcopenia risk doubles after estrogen loss.
Ashwagandha (KSM-66 extract) has the most consistent human RCT data among adaptogens. Its primary application in women is cortisol modulation, which secondarily improves sleep architecture, thyroid function, and perceived stress.
What to measure first. These six markers define your starting point and identify where intervention has the highest leverage.
25-OH Vitamin D
Target: 40–60 ng/mL
The most common deficiency in women over 40. Below 30 ng/mL is associated with accelerated bone loss and elevated cardiovascular risk.
DEXA Scan
Bone mineral density baseline
Establish your T-score at age 50 or earlier if risk factors are present (family history, low body weight, early menopause). This is the anchor measurement for all bone interventions.
ApoB / LDL-P
Cardiovascular risk
More predictive of atherosclerotic event risk than standard LDL-C. Post-menopausal women show accelerated ApoB rises that standard lipid panels underestimate.
HbA1c + Fasting Insulin
Metabolic health
Estrogen loss reduces insulin sensitivity. HbA1c tracks 90-day glucose average; fasting insulin detects insulin resistance before glucose rises — often years earlier.
TSH + Free T4
Thyroid function
Hypothyroidism is 5–8 times more common in women than men, and symptoms overlap heavily with perimenopause. This is among the most frequently missed diagnoses in women 40-55.
Epigenetic Age Test
DunedinPACE or GrimAge
Perimenopause measurably accelerates biological aging. Epigenetic clocks quantify your actual aging rate vs. chronological age, providing the clearest target for intervention effectiveness.
Educational use only. Do not start, stop, or change medications, supplements, or treatment based on this tool.
Clinical Boundary
A Note on Hormone Replacement Therapy
Hormone Replacement Therapy (HRT)
EBL does not grade or recommend specific HRT protocols. HRT decisions involve individual risk factors — including personal and family history of cardiovascular disease, clotting disorders, and hormone-sensitive cancers — that require clinical evaluation by a qualified physician.
If you are considering HRT, use our tools to understand your cardiovascular and bone baseline first, then bring that data to your physician. The interventions graded on this page are evidence-supported independently of HRT and are appropriate whether or not you are on hormone therapy.
Evidence Tools
Use the EBL Tools
Three tools built specifically to help you evaluate your options with actual evidence.